Encorafenib in combination with binimetinib [ENC3]

For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. The patient has a histologically confirmed diagnosis of non-small cell lung cancer (NSCLC).
3. The patient has histological or cytological evidence of NSCLC that contains a BRAF V600E mutation based on a validated test OR there is documented agreement by the lung MDT that the radiological appearances are in keeping with metastatic NSCLC AND there is an informative circulating free DNA test result confirming the presence of a BRAF V600E mutation. Please mark below on which basis the diagnosis of BRAF V600E mutation positive NSCLC has been made in this patient:

• Histological or cytological evidence or
• Documented agreement by the lung MDT that the radiological appearances are in keeping with metastatic NSCLC and there is an informative circulating free DNA test result confirming the presence of a BRAF V600E mutation

4. The patient has metastatic non-small cell lung cancer.
5. The patient is treatment naïve to BRAF and MEK inhibitors for the treatment of metastatic NSCLC, unless the patient was commenced on 1st line dabrafenib and trametinib in this same indication, and these agents had to be discontinued due to unacceptable toxicity, despite suitable trials of dose reduction strategies. Please mark below the relevant option for this patient:

• The patient is treatment naïve to BRAF and MEK inhibitors for the treatment of metastatic NSCLC
• The patient was commenced on 1st line dabrafenib and trametinib in this same indication, and these agents had to be discontinued due to unacceptable toxicity, despite suitable trials of dose reduction strategies.

6. This patient has not received any previous systemic therapy for metastatic NSCLC.

Note

Note: any prior adjuvant or neoadjuvant chemotherapy or immunotherapy for NSCLC does not count as previous systemic therapy in this regard.

7. The patient has an ECOG performance status of either 0 or 1. Please enter below as to which ECOG performance status applies to this patient:

• ECOG PS 0 or
• ECOG PS 1

8. The patient either has no known brain metastases or if the patient has brain metastases, the patient is symptomatically stable prior to starting encorafenib in combination with binimetinib.
9. Treatment with encorafenib in combination with binimetinib will be continued until loss of clinical benefit or unacceptable toxicity or withdrawal of patient consent.
10. Where a treatment break of more than 6 weeks beyond the expected 4 weekly cycle length is needed, I will complete a treatment break approval form to restart treatment, which MUST be approved before treatment is recommenced.
11. Encorafenib in combination with binimetinib is to be otherwise used as set out in their respective Summaries of Product Characteristics.

CDF funded From: 21 April 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.394 of the CDF list, downloaded from NHS England’s website on 24 April 2026 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.